<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940927</url>
  </required_header>
  <id_info>
    <org_study_id>93-41</org_study_id>
    <nct_id>NCT00940927</nct_id>
  </id_info>
  <brief_title>Dose-response of Albuterol in Asthmatics</brief_title>
  <official_title>Exclusion of Asthmatics From Clinical Trials Due to the 15 Percent Rule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the lung function response after increasing doses
      of albuterol (a bronchodilator) in children and adults with asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inhaled short-acting b2-agonists (SABA) are the most potent bronchodilators used today to
      treat acute symptoms of asthma and albuterol, a partial b2-agonist, is the most frequently
      prescribed asthma medication in the US. Although universally used in for acute asthma
      symptoms, SABA have been associated with a significant degree of interpatient variability.
      Many studies have characterized the SABA dose to bronchodilator response relationship under
      controlled conditions. However, few studies have explored the magnitude and sources of
      bronchodilator response variability, and no studies have characterized the dose versus
      bronchodilator response relationship using population pharmacokinetic/pharmacodynamic
      (PPK/PD) modeling. In the present study, we characterized the relationship between inhaled
      doses of albuterol and bronchodilation in 81 children and adults with moderate to severe
      persistent asthma using a population pharmacodynamic approach. The purpose of this study was
      to obtain estimates of the pharmacodynamic parameters that characterize the dose-response
      curve, including maximal dose for bronchodilation, and to quantify and identify sources of
      interpatient pharmacodynamic variability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1993</start_date>
  <completion_date type="Actual">October 1994</completion_date>
  <primary_completion_date type="Actual">October 1994</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective Dose 50% (ED50)</measure>
    <time_frame>15 minutes after each dose</time_frame>
    <description>ED50 is the cumulative dose of albuterol required to bring about 50% of maximum effect of albuterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect Maximum (Emax)</measure>
    <time_frame>15 minutes after each dose</time_frame>
    <description>Maximum percentage of predicted FEV1 effect</description>
  </primary_outcome>
  <enrollment type="Actual">81</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol</intervention_name>
    <description>Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)</description>
    <other_name>Proventil MDI</other_name>
    <other_name>Proventil solution for nebulization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          -  Well-defined history of physician diagnosed asthma

          -  Any ethnic background

          -  8 to 65 years old

          -  Baseline pre-bronchodilator FEV1 of 40% to 80% predicted for age, height, and gender

          -  No oral corticosteroid use, emergency room visits, or hospitalizations within the
             previous 3 months

          -  Nonsmokers or less than a 5 pack-year history with no smoking in the previous year

          -  Normal physical exam and no confounding diseases were selected

          -  Able to withhold inhaled short-acting b2-agonists or inhaled anticholinergic drugs for
             8 hours, oral antihistamines for 5 days, theophylline for 24 hours, and cromolyn,
             nedocromil, and inhaled corticosteroids for 2 hours prior to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn V Blake, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Children's Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Blake K, Madabushi R, Derendorf H, Lima J. Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma. Chest. 2008 Nov;134(5):981-989. doi: 10.1378/chest.07-2991. Epub 2008 Jun 26.</citation>
    <PMID>18583517</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <results_first_submitted>February 3, 2009</results_first_submitted>
  <results_first_submitted_qc>May 28, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 17, 2009</results_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <responsible_party>
    <name_title>Kathryn Blake, Pharm.D.</name_title>
    <organization>Nemours Children's Clinic</organization>
  </responsible_party>
  <keyword>Albuterol</keyword>
  <keyword>Forced expiratory volume in one second</keyword>
  <keyword>Dose at fifty percent of maximum effect</keyword>
  <keyword>Maximum effective dose</keyword>
  <keyword>Metered dose inhaler</keyword>
  <keyword>Nebulizer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from our asthma research clinic database or newspaper advertisements. Participants were recruited from 07/1993 to 10/1994.</recruitment_details>
      <pre_assignment_details>Participants had to withhold inhaled short-acting beta2 agonist or inhaled anticholinergic drugs for 8 h, oral antihistamines for 5 days, theophylline for 24 h, and cromolyn, nedocromil, and inhaled corticosteroids for 2 h prior to the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Albuterol</title>
          <description>Increasing doses of albuterol by MDI and nebulizer solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Albuterol</title>
          <description>Increasing doses of albuterol by MDI and nebulizer solution</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.2" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effective Dose 50% (ED50)</title>
        <description>ED50 is the cumulative dose of albuterol required to bring about 50% of maximum effect of albuterol</description>
        <time_frame>15 minutes after each dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Increasing doses of albuterol by MDI and nebulizer solution</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Dose 50% (ED50)</title>
          <description>ED50 is the cumulative dose of albuterol required to bring about 50% of maximum effect of albuterol</description>
          <units>ug</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect Maximum (Emax)</title>
        <description>Maximum percentage of predicted FEV1 effect</description>
        <time_frame>15 minutes after each dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albuterol</title>
            <description>Increasing doses of albuterol by MDI and nebulizer solution</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Maximum (Emax)</title>
          <description>Maximum percentage of predicted FEV1 effect</description>
          <units>percentage of predicted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Albuterol</title>
          <description>Increasing doses of albuterol by MDI and nebulizer solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathryn Blake, Pharm.D.</name_or_title>
      <organization>Nemours Children's Clinic</organization>
      <phone>904 858 3806</phone>
      <email>kblake@nemours.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

